Article: When It Comes to Drug Eluting Stents, Money Is No Object; Invasive cardiologists report anatomy is deciding factor in drug eluting stent usage.

SOUTH SAN FRANCISCO, Calif., Jan. 20 /PRNewswire/ -- Cost is not a significant factor to cardiologists choosing between drug eluting stents (DES) and bare metal stents (BMS), according to a survey of invasive cardiologists conducted by Medcompare. Survey respondents indicated that price is only rarely a consideration in the decision to use DES over BMS for angioplasty procedures.

Considering that DES can cost three times more than BMS, an added cost not always covered by insurance companies, it wasn't previously clear if price would influence DES usage.

In fact, the survey results showed that cost and insurance coverage are only considered by 28% and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!